Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool

Frankie Ann Holmes, MD, FACP
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Mark D. Pegram, MD
Denise A. Yardley, MD
Released: March 19, 2019

Introduction

The goal of this Interactive Decision Support Tool is to help you better understand your HER2-positive early breast cancer diagnosis and treatment options so that you can become partners with your oncology team in your cancer care.

The tool allows you to enter specific information about your cancer diagnosis using a series of multiple choice questions. Once all of your information is entered, the tool will provide treatment plans chosen by 5 breast cancer experts based on the information that you entered, which you can print and share with your oncologist.

Data were compiled in October 2018 and include the opinions of the experts at that time.

To make the best use of this tool, it is recommended that you have as much information about your cancer as possible before you begin. To assist you in gathering this information, click here for a PDF consultation checklist with helpful questions for your oncologist. For additional tips, please also see “How to Talk to Your Oncologist.”

If you are a healthcare provider, you can find our clinician-focused tool here: www.clinicaloptions.com/HER2_EBC_tool

Interactive Decision Support Tool
Expert Insights on HER2+ EBC
ACCEPT DISCLAIMER AND LAUNCH TOOL
Enter Patient Details

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

The “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool is designed to educate patients on optimal regimens for HER2+ early breast cancer, based on specific patient and disease characteristics. The information provided is based on the expert guidance of breast cancer experts Frankie Ann Holmes, MD, FACP; Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Mark D. Pegram, MD; and Denise A. Yardley, MD.

Although the information contained in the “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. Patients should always discuss their healthcare decisions with their oncology care team. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Grace Logo
This activity is supported by an educational grant from
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings